Sanofi to provide fill/finish services for Moderna COVID-19 vaccine

By The Science Advisory Board staff writers

April 26, 2021 -- Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.

Beginning in September, Sanofi will provide fill/finish sterile manufacturing services and supply packaging for up to 200 million doses of Moderna's COVID-19 vaccine in the U.S., according to Moderna. Sanofi will utilize manufacturing infrastructure at its location in Ridgefield, NJ.

Moderna provides updates on mRNA vaccine platform
Moderna gave updates on its messenger RNA (mRNA) vaccines during its second annual Vaccines Day event. The company plans to continue to invest resources...
Sanofi acquires Tidal Therapeutics, expands vaccine manufacturing
Sanofi announced that it has purchased Tidal Therapeutics for $160 million and plans to expand its vaccine manufacturing capability through a site...
Moderna highlights 6-month antibody persistence of its COVID-19 vaccine
Antibody persistence lasted through six months following the second dose of Moderna's COVID-19 vaccine, according to a study published April 6 in the...
Sanofi to build new manufacturing facility in Toronto
Sanofi announced an investment of approximately $737 million U.S. in a new vaccine manufacturing facility at its existing site in Toronto, Canada,...
GVN adds Sanofi Pasteur as partner against viral threats
The Global Virus Network (GVN) has added Sanofi Pasteur, the vaccines business unit of Sanofi, as a member of the GVN Healthcare & Pharma Centers of Excellence...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter